Trial Profile
Randomized Phase 2 Study of Neoadjuvant Chemotherapy, Carboplatin and Paclitaxel, With or Without Atezolizumab in Triple Negative Breast Cancer (TNBC)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 01 Feb 2024
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Carboplatin; Paclitaxel
- Indications Advanced breast cancer; Early breast cancer; Male breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- 25 Jan 2024 Planned End Date changed from 17 Dec 2024 to 23 Jan 2025.
- 19 Dec 2023 Planned End Date changed from 1 Jul 2023 to 17 Dec 2024.
- 02 Jul 2022 Planned End Date changed from 1 Jul 2022 to 1 Jul 2023.